Mupadolimab( —— )

Catalog No. M36690 CAS No. 2451856-97-4

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Mupadolimab
Note

Research use only, not for human use.
Brief Description

Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.
Description

Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
In Vitro

——
In Vivo

Animal Model:NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)Dosage:10 mg/kg Administration:Intraperitoneal injection, daily for 15 days Result:Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

CD73
Research Area

——
Indication

——

1. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021.

Calculator

molnova catalog